Increased frequency of canine distemper virus-specific antibodies in multiple sclerosis.
antibodies
canine distemper virus
multiple sclerosis
peptide ELISA
Journal
Brain and behavior
ISSN: 2162-3279
Titre abrégé: Brain Behav
Pays: United States
ID NLM: 101570837
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
24
03
2020
revised:
13
08
2020
accepted:
07
10
2020
pubmed:
11
12
2020
medline:
1
7
2021
entrez:
10
12
2020
Statut:
ppublish
Résumé
Canine distemper virus (CDV) is a candidate agent in the etiology of multiple sclerosis (MS). Elevated anti-CDV levels were previously found in the sera from MS patients compared with controls. We now investigated whether there was an age-related association with the presence of antibodies specific to CDV-hemagglutinin (H) protein in MS. Sera from patients with MS, other neurological diseases, and inflammatory and/or autoimmune diseases, and healthy individuals were screened for anti-CDV in an ELISA using linear peptides of the CDV-H protein as antigen. Antibody levels to measles and varicella-zoster virus were measured and served as controls. Analysis of the new cohort of MS patients and controls confirmed our initial finding of elevated anti-CDV-H levels in MS patients. An increase in measles but not varicella-zoster virus antibody levels was found in MS patients compared with healthy controls. Data from the new cohort of patients and controls were combined with data from the original study and analyzed with respect to age distribution of anti-CDV IgG. Mean CDV antibody levels were significantly elevated in each decade from 20 to 50 years of age in MS compared with healthy and disease controls. Antibody levels to measles virus were not consistently elevated during this age span. A striking relationship (p < .0001, odds ratio = 5.0) was observed between elevated anti-CDV-H levels and diagnosis of MS. The finding that anti-CDV levels are elevated in MS patients of all ages provides substantial evidence of a strong association between elevated anti-CDV and MS.
Sections du résumé
BACKGROUND AND PURPOSE
Canine distemper virus (CDV) is a candidate agent in the etiology of multiple sclerosis (MS). Elevated anti-CDV levels were previously found in the sera from MS patients compared with controls. We now investigated whether there was an age-related association with the presence of antibodies specific to CDV-hemagglutinin (H) protein in MS.
METHODS
Sera from patients with MS, other neurological diseases, and inflammatory and/or autoimmune diseases, and healthy individuals were screened for anti-CDV in an ELISA using linear peptides of the CDV-H protein as antigen. Antibody levels to measles and varicella-zoster virus were measured and served as controls.
RESULTS
Analysis of the new cohort of MS patients and controls confirmed our initial finding of elevated anti-CDV-H levels in MS patients. An increase in measles but not varicella-zoster virus antibody levels was found in MS patients compared with healthy controls. Data from the new cohort of patients and controls were combined with data from the original study and analyzed with respect to age distribution of anti-CDV IgG. Mean CDV antibody levels were significantly elevated in each decade from 20 to 50 years of age in MS compared with healthy and disease controls. Antibody levels to measles virus were not consistently elevated during this age span. A striking relationship (p < .0001, odds ratio = 5.0) was observed between elevated anti-CDV-H levels and diagnosis of MS.
CONCLUSIONS
The finding that anti-CDV levels are elevated in MS patients of all ages provides substantial evidence of a strong association between elevated anti-CDV and MS.
Identifiants
pubmed: 33300690
doi: 10.1002/brb3.1920
pmc: PMC7821626
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e01920Informations de copyright
© 2020 The Authors. Brain and Behavior published by Wiley Periodicals LLC.
Références
Rev Med Chir Soc Med Nat Iasi. 1986 Oct-Dec;90(4):673-7
pubmed: 3602723
Ann Neurol. 1983 Mar;13(3):227-31
pubmed: 6847134
JAMA. 2001 Dec 26;286(24):3083-8
pubmed: 11754673
Brain Behav. 2021 Jan;11(1):e01920
pubmed: 33300690
Neurology. 1984 Sep;34(9):1149-54
pubmed: 6540401
Scand J Work Environ Health. 1993 Dec;19(6):399-404
pubmed: 8153592
Ann Neurol. 1982 Feb;11(2):192-4
pubmed: 7073251
Arch Neurol. 1983 Apr;40(4):213-4
pubmed: 6830470
Acta Neurol Scand. 1997 Feb;95(2):90-5
pubmed: 9059727
J Neurol Sci. 1982 Sep;55(3):359-67
pubmed: 7131040
Arch Neurol. 1988 Jun;45(6):620-3
pubmed: 3369968
Ann Neurol. 1978 Feb;3(2):141-3
pubmed: 655663
Mult Scler Relat Disord. 2016 Nov;10:53-56
pubmed: 27919498
Neurology. 1972 May;22(5):492-9
pubmed: 4673445
Lancet. 1979 Feb 17;1(8112):380-1
pubmed: 85027
Semin Neurol. 2011 Jul;31(3):307-16
pubmed: 21964847
Mult Scler Relat Disord. 2019 Jan;27:327-332
pubmed: 30471586
Lancet. 1987 Jun 20;1(8547):1426-7
pubmed: 2884509
JAMA. 2005 May 25;293(20):2496-500
pubmed: 15914750
JAMA. 1977 Aug 22;238(8):854
pubmed: 577970
Ann Neurol. 2010 Feb;67(2):159-69
pubmed: 20225269
Neurology. 1999 Nov 10;53(8):1711-8
pubmed: 10563617
Proc Natl Acad Sci U S A. 1981 Jun;78(6):3824-8
pubmed: 6167991
Acta Neuropathol. 1989;77(4):441-4
pubmed: 2711831
Lancet. 1977 Nov 12;2(8046):1029
pubmed: 72925
Proc Soc Exp Biol Med. 1962 Dec;111:562-6
pubmed: 14011000
Can Med Assoc J. 1982 Feb 15;126(4):377-82, 385
pubmed: 7066795
Lancet. 1977 May 7;1(8019):980-2
pubmed: 67471
Arch Neurol. 2006 Jun;63(6):839-44
pubmed: 16606758
Lancet. 1978 Mar 18;1(8064):605-6
pubmed: 76140
Neurol Clin. 2008 Aug;26(3):699-715, viii
pubmed: 18657722
Neurology. 1995 Aug;45(8):1554-60
pubmed: 7543986
J Neurol Sci. 1980 Sep;47(3):429-32
pubmed: 7420118
Clin Exp Immunol. 1973 Jul;14(3):409-16
pubmed: 4353489
Science. 1985 Nov 29;230(4729):1043-5
pubmed: 2414848
Acta Neuropathol. 1982;56(4):285-93
pubmed: 7090737